<DOC>
	<DOCNO>NCT01109693</DOCNO>
	<brief_summary>The purpose study establish optimum treatment strategy first-line second-line antidepressant acute phase treatment major depression .</brief_summary>
	<brief_title>Strategic Use New Generation Antidepressants Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>nonpsychotic unipolar major depressive episode ( Diagnostic Statistical Manual , Fourth Edition [ DSMIV ] ) precede month age 2575 start treatment sertraline clinically indicated tolerability sertraline 25 mg/d ascertain understand sign inform consent form contact telephone symptom severity adverse event receive antidepressant , mood stabilizer , antipsychotic , psychostimulants , electroconvulsive therapy ( ECT ) depressionspecific psychotherapy precede month history schizophrenia , schizoaffective disorder bipolar disorder current dementia , borderline personality disorder , eat disorder substance dependence physical disease interfere sertraline mirtazapine treatment allergy sertraline mirtazapine terminal physical illness currently pregnant breastfeed high risk imminent suicide require compulsory admission expect change doctor within 6 month cohabit relative research staff understand Japanese</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>